1 Westmount Square
44 articles with AmorChem l.p.
AmorChem Invests in the Work of Sidong Huang at McGill University Using a Novel Target to Address a SMARCA4-deficient Rare and Aggressive Form of Ovarian Cancer
AmorChem Invests in the Work of Sidong Huang at McGill University Using a Novel Target to Address a SMARCA4-deficient Rare and Aggressive Form of Ovarian Cancer MONTREAL--( BUSINESS WIRE )-- AmorChem II L.P. (“AmorChem”) is proud to announce the closing of a new transaction with McGill University (“McGill”), focusing on the work of Dr. Sidong Huang and his collaborator, Dr. Martin Schmeing, from the Rosalind and Morris Goodman Cancer Research Centre. The
AmorChem is proud to announce a new investment in a research program hailing from Université Laval and the Research Center of the Centre Hospitalier Universitaire de Québec. The venture capital fund identified the opportunity in close collaboration with SOVAR, a group active in the promotion of university research. Am
Toronto Innovation Acceleration Partners, Evotec SE and AmorChem II Fund L.P. are pleased to announce a $1.75M investment into a drug development project focused on a rare skin disease called Netherton Syndrome, that affects one in 200,000 newborns worldwide.
AmorChem II is proud to announce the financing of a collaboration centered around c-Myc, a proto-oncogene implicated in over 50% of all human cancers.
AmorChem is proud to announce a first investment at the Université de Sherbrooke.
Back by popular demand, AmorChem, the innovative Quebec-based seed venture capital fund, is hosting the 5th edition of its KNOCK OUT Event.
AmorChem, a leading venture fund dedicated to creating the next generation of biotech companies derived from academic research, introduced its rebranding this week.
Back by popular demand, AmorChem, the innovative Quebec-based seed venture capital fund, is hosting the 5thedition of its KNOCK OUTTM Event, a challenge where the Contenders, academic researchers selected by AmorChem, duke it out in the ring against a panel of Heavyweight champions in order to qualify for a $500,000 financing from AmorChem.
AmorChem Reinforces Its Innate Immunity Franchise with an Investment in Checkpoint Control Target SRSF3
AmorChem II is very proud to announce the financing of a new university project.
AmorChem is hosting its fifth KNOCK OUT Event during the 1st edition of the EFFERVERSCENCE conference, April 24th, 2019 in Montreal.
AmorChem II is proud to announce the closing of its first financing of a university project.
AmorChem Spins out Its Muco-Adhesive Nanoparticle Delivery Platform into MyX Therapeutics, with 450,000$ Seed Investment.
This capital will allow MyX to clinch its first deals with commercial partners, targeting primarily ocular diseases in both animal and human health.
AmorChem was built through the vision and leadership of its two founders, Elizabeth Douville and Inès Holzbaur, making it one of the rare venture capital funds led by two women.
11/5/2018Biopharma companies make key appointments to fill leadership positions. Let's take a look!
AmorChem selected these highly qualified individuals because collectively, they offer an enviable array of diversified expertise and experience in lifesciences venture capital investment, drug discovery and pharmaceutical development.
AmorChem l.p. Release: Company Spins Out Its SEMA 3A Technology Into Semathera, With 1M$ Seed Investment
AmorChem l.p. Spins Out Its Usp15-Deubiquitinylation (Dub) Drug Discovery Platform Into Corbin Therapeutics, With A First 1M$ Seed Investment